AGRN and sarcopenia: The destabilisation of the NMJ and loss of skeletal muscle mass, which occur due to excessive degradation of agrin in mouse models [20,21,22], are reversed by overexpression or intravenous injection of the cleavage-resistant neuronal agrin [21,23], suggesting that pharmacological therapies that enhance agrin signalling might be effective in some forms or stages of sarcopenia.